Skip to content

Comparison Study of Two Supraglottic Airway Devices Used for Patients Under General Anesthesia

Prospective Randomized Trial Comparing the Performance of Two Supraglottic Airway Management Devices: I-Gel and Supreme LMA

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01001078
Enrollment
100
Registered
2009-10-23
Start date
2009-09-30
Completion date
2011-03-31
Last updated
2015-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia Airway Management

Keywords

supraglottic airway devices, I-Gel, Supreme Laryngeal mask airway, Airway leak pressure, peak airway pressure

Brief summary

This study will compare two supraglottic airway devices currently on the market. Supraglottic airway devices are used during general anesthesia to provide a patent airway. They are inserted blindly into the mouth once the patient has lost consciousness and they cover the laryngeal inlet. The I-Gel and the Supreme laryngeal mask airway (LMA) are the two devices to be compared. The I-Gel has no inflatable cuff, which makes it different from all other supraglottic airway devices currently in use. The Supreme shares some characteristics of the other LMA devices, but it is disposable. Our main goal will be to compare the airway leak pressure and the peak airway pressure of each devices. We will also measure the time needed for insertion, number of attempts needed to secure the airway and side effects related to the airway (cough, dysphagia, trauma, hoarseness of voice, sore throat).

Detailed description

First of all, we will record the following demographic variables: age, sex, height, weight, BMI, surgery planned, American Society of Anesthesiology (ASA) status, dental state (good, bad, edentulous), tobacco use (none, ceased, active) and packs year, Mallampati score, thyromental distance and whether or not there is trauma on the tongue, teeth or lips prior to surgery. Induction of anesthesia will be standardized with Fentanyl 1-3 mcg/kiloGram(kG) and Propofol 1-3,5 mg/kG. The use of myorelaxant will be mandatory, but either succinylcholine or rocuronium will be used as long as complete disappearance of T1 is observed before attempting supraglottic airway insertion. Prior to insertion, ease of ventilation (yes/no) will be noted. The two airway devices will be used according to manufacturers instructions. The sizes of the devices will be chosen according to weight: I-Gel: 50-90 kG: #4 and 90 Kg and up: #5 LMA Supreme: 50-70 Kg: #4 and 70-100 Kg: #5. Patients will be randomized in either I-Gel or LMA Supreme group. Two insertions with the same device will be allowed before a crossover to the other device. If the third attempt fails, a standard endotracheal tube will be put in the trachea and blood in the oral cavity will be sought. After each failed attempt (no thoracic expansion, no carbon dioxide (CO2) square wave or leak at standardized volume. Blood on the devices will also be recorded. Since the LMA Supreme has a cuff, we will inflate it to 25 mL and then by intervals of 5 mL of air (max 45 mL) we will inflate it at a volume where no audible leak is heard at a standardized ventilation scheme of volume controlled 8 mL/kg X 10 breaths per minute. Once fixed with tape, we will measure peak and mean airway pressure for three breaths after 30 seconds of volume controlled breathing. Then the fresh gas flow will be fixed at 3 L/min of 50-50 air-oxygen blend and the Adjustable Pressure Limiting valve will be closed. We will look either for a plateau pressure at which a leak equal to the fresh gas flow or a pressure of 40 cm of water. We will sought adverse effect like bronchospasm, cough, regurgitation, desaturation, aspiration and deglutition movement. Ease of insertion will be score on a scale of 1 to 4. 1 being very easy and 4 being very hard. Endoscopic evaluation will take place afterwards. First in the ventilation tube. Scoring for laryngeal view: 1. Vocal cords all visible; 2. Partial view of the cords including arytenoids; 3. View of the epiglottis only; 4. Other (LMA or pharynx). Downfolding of the epiglottis will be sought. Then we will go through the oesophageal port and see if the oesophageal mucosa il visible. During surgery, we will check if airway manipulation and/or withdrawal was necessary and why. If traces of blood on the devices are present at the end of the intervention it will be noted. Two interviews will take place one at the post anesthesia care unit and another the following day by phone if the patient was having ambulatory surgery. Sore throat, cough, dysphagia and dysphonia will be asked to be graded: absent, mild, moderate or severe. Pulse and arterial pressure with the operating room's sphygmomanometer and oximeter will be written before induction, after induction before insertion and at 1 and 2 minutes post insertion.

Interventions

2 attempts to secure the airway will be tried. If they both fail, there will be a crossover with a Supreme LMA.

DEVICELMA Supreme supraglottic airway device

In the LMA Supreme group, the same interventions will be done as in the I-Gel group. The cuff of the LMA Supreme will be inflated with 25 mL of air and then by intervals of 5 mL until no leak is heard (max 45 mL). Leak pressure will also be measure at 45 mL. Once the leak test is done, the cuff will be deflated to initial volume necessary to avoid audible leaks.

In case both supraglottic airway devices fail, a standard endotracheal tube will be inserted

Sponsors

Maisonneuve-Rosemont Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Weight more than 50 kg; * Body Mass Index less than 30; * ASA I to III.

Exclusion criteria

* Symptomatic gastro oesophageal reflux disease (GERD); * Non fasted patients; * Nasogastric tube in place; * Intestinal obstruction; * Ear, nose and throat surgery in the past or deformation of the airway; * Known difficult airway (Cormack-Lehane grade 3-4); * Oral cavity opening less than 3 cm; * Pregnancy.

Design outcomes

Primary

MeasureTime frame
Measure of the Airway Leak PressureAfter introduction of the supraglottic device before the beginning of the surgery.

Secondary

MeasureTime frameDescription
Measure of the Peak Airway PressureAfter introduction of the SAD before the beginning of the surgery.
Time Needed to Secure the AirwayFrom opening of the mouth to thoracic expansion and presence of End Tidal CO2 up to five minutes.
Number of Participants With Successful Attempts to Introduce the DevicesAt the beginning of anesthesia before the beginning of the surgery.
Adverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)On the day following surgeryIntent to treat assessment of adverse events, per intervention, was intended. The adverse effects were assessed by phone; or in person if patient in the hospital; on the following day.
Airway Manipulation and Blood on Device at RemovalDuring and after anesthesia when the device is removed.

Countries

Canada

Participant flow

Recruitment details

Recruitment was done at a university hospital mainly in the ambulatory surgery unit from september 2009 to april 2011. 50 patients were recruited in 2009, one fourth in 2010 and the last fourth in 2011. 311 patients were assessed for eligibility, 211 were excluded. 178 did not meet inclusion criteria and 33 declined to participate.

Participants by arm

ArmCount
I-Gel
Group in which the I-Gel will be used in the first and second attempts to secure the airway. If a third attempt is needed, the LMA Supreme will be used. If the third attempt fails, a standard endotracheal tube will be used. Peak and mean airway pressure will be measured once the device is fixed with tape to the patient. Leak pressure will be measured as well. It will be done while closing the Adjustable Pressure Limiting valve and putting the fresh gas flow at 3 L/min. We will be looking at the manometer to see either a plateau (that would be a leak equal to the fresh gas flow) or the maximum allowed pressure 40 cm H2O.
50
LMA Supreme
Group in which the LMA Supreme will be used in the first and second attempts to secure the airway. If a third attempt is needed, the I-Gel will be used. If the third attempt fails, a standard endotracheal tube will be used. The cuff of the LMA Supreme will be inflated with 25 mL of air and then by intervals of 5 mL until no leak is heard (max 45 mL). Peak and mean airway pressure will be measured once the device is fixed with tape to the patient. Leak pressure will be measured at a cuff volume without audible leak and also at 45 mL. It will be done while closing the Adjustable Pressure Limiting valve and putting the fresh gas flow at 3 L/min. We will be looking at the manometer to see either a plateau (that would be a leak equal to the fresh gas flow) or the maximum allowed pressure 40 cm H2O. Once the leak tests are done, the cuff will be deflated to initial volume necessary to avoid audible leaks.
50
Total100

Baseline characteristics

CharacteristicLMA SupremeTotalI-Gel
Age, Continuous50 years
STANDARD_DEVIATION 18
50 years
STANDARD_DEVIATION 17
50 years
STANDARD_DEVIATION 16
BMI26 kg/m^2
STANDARD_DEVIATION 4
26 kg/m^2
STANDARD_DEVIATION 4
26 kg/m^2
STANDARD_DEVIATION 4
Height1.67 meters
STANDARD_DEVIATION 0.1
1.68 meters
STANDARD_DEVIATION 0.095
1.68 meters
STANDARD_DEVIATION 0.09
Sex: Female, Male
Female
37 Participants70 Participants33 Participants
Sex: Female, Male
Male
13 Participants30 Participants17 Participants
Weight71 kilograms
STANDARD_DEVIATION 13
71.5 kilograms
STANDARD_DEVIATION 12
72 kilograms
STANDARD_DEVIATION 11

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
23 / 5031 / 50
serious
Total, serious adverse events
0 / 500 / 50

Outcome results

Primary

Measure of the Airway Leak Pressure

Time frame: After introduction of the supraglottic device before the beginning of the surgery.

ArmMeasureValue (MEAN)Dispersion
I-GelMeasure of the Airway Leak Pressure23 cmH2OStandard Deviation 7
LMA SupremeMeasure of the Airway Leak Pressure21 cmH2OStandard Deviation 8
Secondary

Adverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)

Intent to treat assessment of adverse events, per intervention, was intended. The adverse effects were assessed by phone; or in person if patient in the hospital; on the following day.

Time frame: On the day following surgery

Population: 5 participants were lost to follow-up and 4 participants had the crossover device or were intubated in the I-Gel group.~4 participants were lost to follow-up and 3 participants had the crossover device or were intubated in the LMA Supreme group (one of participants was lost to follow-up and had the crossover device or was intubated)

ArmMeasureGroupValue (NUMBER)
I-GelAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Sore Throat (mild)10 participants
I-GelAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Sore Throat (absent)23 participants
I-GelAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Sore Throat (moderate)6 participants
I-GelAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Sore Throat (severe)2 participants
I-GelAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Cough (absent)36 participants
I-GelAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Cough (mild)5 participants
I-GelAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Cough (moderate)0 participants
I-GelAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Cough (severe)0 participants
I-GelAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Dysphagia (absent)25 participants
I-GelAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Dysphagia (mild)7 participants
I-GelAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Dysphagia (moderate)9 participants
I-GelAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Dysphagia (severe)0 participants
I-GelAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Dysphonia (absent)34 participants
I-GelAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Dysphonia (mild)5 participants
I-GelAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Dysphonia (moderate)1 participants
I-GelAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Dysphonia (severe)1 participants
LMA SupremeAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Dysphonia (severe)1 participants
LMA SupremeAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Dysphagia (absent)29 participants
LMA SupremeAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Sore Throat (absent)26 participants
LMA SupremeAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Sore Throat (mild)13 participants
LMA SupremeAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Dysphonia (absent)35 participants
LMA SupremeAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Sore Throat (moderate)4 participants
LMA SupremeAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Dysphagia (mild)9 participants
LMA SupremeAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Sore Throat (severe)1 participants
LMA SupremeAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Dysphonia (moderate)3 participants
LMA SupremeAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Cough (absent)38 participants
LMA SupremeAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Dysphagia (moderate)4 participants
LMA SupremeAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Cough (mild)5 participants
LMA SupremeAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Dysphonia (mild)5 participants
LMA SupremeAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Cough (moderate)1 participants
LMA SupremeAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Dysphagia (severe)2 participants
LMA SupremeAdverse Effects After Anesthesia (Sore Throat, Cough, Dysphagia, Dysphonia)Cough (severe)0 participants
Secondary

Airway Manipulation and Blood on Device at Removal

Time frame: During and after anesthesia when the device is removed.

ArmMeasureGroupValue (NUMBER)
I-GelAirway Manipulation and Blood on Device at RemovalRepositionning during surgery2 participants
I-GelAirway Manipulation and Blood on Device at RemovalBlood on device at removal5 participants
LMA SupremeAirway Manipulation and Blood on Device at RemovalRepositionning during surgery3 participants
LMA SupremeAirway Manipulation and Blood on Device at RemovalBlood on device at removal6 participants
Secondary

Measure of the Peak Airway Pressure

Time frame: After introduction of the SAD before the beginning of the surgery.

ArmMeasureValue (MEAN)Dispersion
I-GelMeasure of the Peak Airway Pressure14 cm H20Standard Deviation 3
LMA SupremeMeasure of the Peak Airway Pressure14 cm H20Standard Deviation 5
Secondary

Number of Participants With Successful Attempts to Introduce the Devices

Time frame: At the beginning of anesthesia before the beginning of the surgery.

ArmMeasureGroupValue (NUMBER)
I-GelNumber of Participants With Successful Attempts to Introduce the Devices1st attempt successful43 participants
I-GelNumber of Participants With Successful Attempts to Introduce the Devices2nd attempt successful3 participants
I-GelNumber of Participants With Successful Attempts to Introduce the DevicesCrossover device2 participants
I-GelNumber of Participants With Successful Attempts to Introduce the DevicesIntubation2 participants
LMA SupremeNumber of Participants With Successful Attempts to Introduce the DevicesIntubation1 participants
LMA SupremeNumber of Participants With Successful Attempts to Introduce the Devices1st attempt successful44 participants
LMA SupremeNumber of Participants With Successful Attempts to Introduce the DevicesCrossover device3 participants
LMA SupremeNumber of Participants With Successful Attempts to Introduce the Devices2nd attempt successful2 participants
Secondary

Time Needed to Secure the Airway

Time frame: From opening of the mouth to thoracic expansion and presence of End Tidal CO2 up to five minutes.

ArmMeasureValue (MEAN)Dispersion
I-GelTime Needed to Secure the Airway19 secondsStandard Deviation 7
LMA SupremeTime Needed to Secure the Airway27 secondsStandard Deviation 17

Source: ClinicalTrials.gov · Data processed: Mar 19, 2026